Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 09, 2021

SELL
$282.99 - $369.05 $7.02 Million - $9.16 Million
-24,812 Closed
0 $0
Q2 2021

Jul 15, 2021

SELL
$259.0 - $414.71 $182,854 - $292,785
-706 Reduced 2.77%
24,812 $8.59 Million
Q1 2021

Apr 23, 2021

BUY
$242.95 - $284.63 $230,073 - $269,544
947 Added 3.85%
25,518 $7.14 Million
Q4 2020

Feb 24, 2021

BUY
$236.26 - $355.63 $9,450 - $14,225
40 Added 0.16%
24,571 $6.02 Million
Q3 2020

Oct 23, 2020

BUY
$264.77 - $305.71 $976,471 - $1.13 Million
3,688 Added 17.69%
24,531 $6.96 Million
Q2 2020

Aug 04, 2020

BUY
$258.66 - $342.55 $49,921 - $66,112
193 Added 0.93%
20,843 $5.58 Million
Q1 2020

May 05, 2020

SELL
$268.85 - $341.04 $42,478 - $53,884
-158 Reduced 0.76%
20,650 $6.53 Million
Q4 2019

Jan 31, 2020

BUY
$220.06 - $304.07 $898,945 - $1.24 Million
4,085 Added 24.43%
20,808 $6.17 Million
Q3 2019

Oct 21, 2019

BUY
$217.44 - $243.88 $2.02 Million - $2.27 Million
9,307 Added 125.5%
16,723 $3.89 Million
Q1 2019

Apr 09, 2019

SELL
$216.71 - $338.96 $508,618 - $795,539
-2,347 Reduced 24.04%
7,416 $2.43 Million
Q4 2018

Jan 15, 2019

SELL
$278.5 - $352.75 $47,066 - $59,614
-169 Reduced 1.7%
9,763 $2.94 Million
Q3 2018

Oct 12, 2018

BUY
$293.51 - $383.83 $557,375 - $728,893
1,899 Added 23.64%
9,932 $3.51 Million
Q2 2018

Aug 07, 2018

SELL
$257.52 - $306.91 $2.07 Million - $2.47 Million
-8,033 Reduced 50.0%
8,033 $2.33 Million
Q2 2018

Jul 17, 2018

BUY
$257.52 - $306.91 $566,544 - $675,202
2,200 Added 15.87%
16,066 $4.66 Million
Q1 2018

Apr 20, 2018

BUY
$260.13 - $367.91 $1.54 Million - $2.17 Million
5,902 Added 74.11%
13,866 $3.8 Million
Q4 2017

Jan 12, 2018

BUY
$307.64 - $344.58 $2.45 Million - $2.74 Million
7,964
7,964 $2.54 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Broadleaf Partners, LLC Portfolio

Follow Broadleaf Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Broadleaf Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Broadleaf Partners, LLC with notifications on news.